The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 49 | — | 20.1x | Near average | |
Growth | 13 | — | 5.6% | Below average | |
Quality | 10 | -107.2% | 7.6% | Below average | |
Safety | 45 | 2.2x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Jade Biosciences, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Jade Biosciences, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Jade Biosciences (JBIO) stock witnessed a notable positive shift in analyst estimates over the past week, with the average target price rising by 17.09% to reach $44.2 compared to $37.75 previously. This increase occurred despite the number of analysts remaining constant (3 analysts), indicating a strong upward revision by current analysts of the stock's fair value, with a wide price gap between the low ($34) and high ($55) reflecting varying expectations regarding the speed of clinical achievement.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.